💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Velaglucerase Alfa

CHEMBL1201865 Phase 4 Đã phê duyệt Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Velaglucerase alfa is a recombinant human lysosomal enzyme (glucocerebrosidase) produced in plant cell culture that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, replacing the deficient enzyme in patients with type 1 Gaucher disease. Administered by intravenous infusion, it is taken up by macrophages via mannose receptors and reduces the pathological accumulation of glucocerebroside in the liver, spleen, and bone marrow. Its plant cell expression system results in mannose-terminated N-glycans that enhance uptake efficiency.

Cơ chế tác dụng

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Velaglucerase alfa is a recombinant human lysosomal enzyme (glucocerebrosidase) produced in plant cell culture that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, replacing the deficient enzyme in patients with type 1 Gaucher disease. Administered by intravenous infusion, it is taken up by macrophages via mannose receptors and reduces the pathological accumulation of glucocerebroside in the liver, spleen, and bone marrow. Its plant cell expression system results in mannose-terminated N-glycans that enhance uptake efficiency.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Velaglucerase Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201865. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.